ASCEND Talking Diabetes
ASCEND Talking Diabetes Podcast
ASCEND Talking Diabetes
10. Which people with type 2 diabetes would benefit from SGLT-2 inhibitors and GLP-1 receptor agonists?
•
Ascend Diabetes
•
Season 1
•
Episode 10
Listen to Professor Liebl outline when and how he uses these modern agents.
Learning objective: Following this activity, you will be able to confidently identify individuals in whom SGLT-2 inhibitors and GLP-1 receptor agonists are likely to be the preferred therapeutic option after metformin.